Wave Life Sciences to Highlight Leading RNA Editing Capabili

Presentations include new data showing WVE-006 improved markers of liver disease in mice; WVE-006 is a first-in-class RNA editing therapeutic for alpha-1 antitrypsin deficiency which is designed to... | May 16, 2023

Related Keywords

United States , Cambridge , Cambridgeshire , United Kingdom , California , American , Kate Rausch , Los Angeles , Wei Liu , Chikdu Shivalila , Chandra Vargeese , Pachamuthu Kandasamy , Prashant Monian , Nasdaq , Wave Life Sciences Nasdaq , Biology At Wave Life Sciences , Exchange Commission , Wave Life Sciences Ltd , Medicinal Chemistry At Wave Life Sciences , American Society , Wave Life Sciences , Life Sciences , Cell Therapy , Annual Meeting , Chief Technology Officer , Wave Life , Senior Scientist , Acid Therapeutics , Oral Abstract , Vice President , Medicinal Chemistry , Poster Session , Investor Relations , Private Securities Litigation Reform Act , Annual Report , Wave Life Sciences Ltd Stock Exchange , News , Information , Press Release , Presentations , Nclude , Few , Data , Showing , Mproved , Markers , F , Liver , Disease , N , Us , Na , Editing , Herapeutic , Or , Ntitrypsin , Deficiency , Which , Esigned Wve Sg9999014716 ,